Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.
复制标题
DOI：
10.1001/jama.2015.4668
复制
发表时间：
2015-05-19
影响因子：
120.7
通讯作者：
Visser, Pieter Jelle
中科院分区：
文献类型：
--
作者：
Jansen, Willemijn J.;Ossenkoppele, Rik;Knol, Dirk L.;Tijms, Betty M.;Scheltens, Philip;Verhey, Frans R. J.;Visser, Pieter Jelle
脑淀粉样蛋白-β聚集是阿尔茨海默病（AD）的早期病理事件，在痴呆发作前几十年就开始了。需要估计非痴呆患者淀粉样病变的患病率，以了解AD的发展和设计预防研究。使用个体受试者数据荟萃分析来估计在认知正常、主观认知障碍（SCI）或轻度认知障碍（MCI）受试者中使用生物标志物测量的淀粉样蛋白病理学的患病率。通过使用MEDLINE和Web of Science数据库检索2015年4月之前发表的研究以及通过与研究者的个人沟通确定的相关生物标志物研究。如果研究提供了没有痴呆的参与者的个人数据，并使用了淀粉样蛋白阳性的先验定义的截止值，则将其纳入研究。从55项研究中，为2914名认知正常的参与者，697名SCI参与者和3972名MCI参与者提供了18至100岁的个人记录。根据AD风险因素（年龄、载脂蛋白E [APOE]基因型、性别和教育程度）通过广义估计方程估计的正电子发射断层扫描或脑脊液中淀粉样病变的患病率。从50岁到90岁，淀粉样病变的患病率从10%增加到10%。（95% CI，8%-13%）至44%（95% CI，37%-51%），认知正常的参与者;从12%在SCI患者中从27%（95%CI，8%-18%）到43%（95%CI，32%-55%）;在MCI患者中从27%（95%CI，23%-32%）到71%（95%CI，66%-76%）。APOE-ε4携带者的患病率估计值比非携带者高2 - 3倍。15%认知正常的参与者淀粉样蛋白阳性的年龄约为40岁（APOEε4ε4携带者）、50岁（ε2ε4携带者）、55岁（ε3ε4携带者）、65岁（ε3ε3携带者）和95岁（ε2ε3携带者）。淀粉样蛋白阳性在受过高等教育的参与者中更常见，但与性别或生物标志物模式无关。在无痴呆的人群中，正电子发射断层扫描或脑脊液检查发现脑淀粉样病变的患病率与年龄、APOE基因型和认知功能障碍相关。这些发现表明，在淀粉样蛋白阳性的第一次发展和痴呆症的发作之间有20到30年的间隔。
Cerebral amyloid-β aggregation is an early pathological event in Alzheimer disease (AD), starting decades before dementia onset. Estimates of the prevalence of amyloid pathology in persons without dementia are needed to understand the development of AD and to design prevention studies. To use individual participant data meta-analysis to estimate the prevalence of amyloid pathology as measured with biomarkers in participants with normal cognition, subjective cognitive impairment (SCI), or mild cognitive impairment (MCI). Relevant biomarker studies identified by searching studies published before April 2015 using the MEDLINE and Web of Science databases and through personal communication with investigators. Studies were included if they provided individual participant data for participants without dementia and used an a priori defined cutoff for amyloid positivity. Individual records were provided for 2914 participants with normal cognition, 697 with SCI, and 3972 with MCI aged 18 to 100 years from 55 studies. Prevalence of amyloid pathology on positron emission tomography or in cerebrospinal fluid according to AD risk factors (age, apolipoprotein E [APOE] genotype, sex, and education) estimated by generalized estimating equations. The prevalence of amyloid pathology increased from age 50 to 90 years from 10% (95% CI, 8%-13%) to 44% (95% CI, 37%-51%) among participants with normal cognition; from 12% (95% CI, 8%-18%) to 43% (95% CI, 32%-55%) among patients with SCI; and from 27% (95% CI, 23%-32%) to 71% (95% CI, 66%-76%) among patients with MCI. APOE-ε4 carriers had 2 to 3 times higher prevalence estimates than noncarriers. The age at which 15% of the participants with normal cognition were amyloid positive was approximately 40 years for APOEε4ε4 carriers, 50 years for ε2ε4 carriers, 55 years for ε3ε4 carriers, 65 years for ε3ε3 carriers, and 95 years for ε2ε3 carriers. Amyloid positivity was more common in highly educated participants but not associated with sex or biomarker modality. Among persons without dementia, the prevalence of cerebral amyloid pathology as determined by positron emission tomography or cerebrospinal fluid findings was associated with age, APOEgenotype, and presence of cognitive impairment. These findings suggest a 20- to 30-year interval between first development of amyloid positivity and onset of dementia.
登录
查看更多内容
影响因子：
2.6
作者：
Amariglio RE;Becker JA;Carmasin J;Wadsworth LP;Lorius N;Sullivan C;Maye JE;Gidicsin C;Pepin LC;Sperling RA;Johnson KA;Rentz DM
通讯作者：
Rentz DM
影响因子：
5.3
作者：
Boehm-Cagan, Anat;Michaelson, Daniel M.
通讯作者：
Michaelson, Daniel M.
影响因子：
15.8
作者：
Matthews, F;Brayne, C
通讯作者：
Brayne, C
DOI：
10.1016/j.jalz.2013.01.010
发表时间：
2013-05
期刊：
Alzheimer's & dementia : the journal of the Alzheimer's Association
影响因子：
--
作者：
Mattsson N;Andreasson U;Persson S;Carrillo MC;Collins S;Chalbot S;Cutler N;Dufour-Rainfray D;Fagan AM;Heegaard NH;Robin Hsiung GY;Hyman B;Iqbal K;Kaeser SA;Lachno DR;Lleó A;Lewczuk P;Molinuevo JL;Parchi P;Regeniter A;Rissman RA;Rosenmann H;Sancesario G;Schröder J;Shaw LM;Teunissen CE;Trojanowski JQ;Vanderstichele H;Vandijck M;Verbeek MM;Zetterberg H;Blennow K;Alzheimer's Association QC Program Work Group
通讯作者：
Alzheimer's Association QC Program Work Group
影响因子：
4
作者：
Lin, Yuh-Te;Cheng, Jiin-Tsuey;Lu, Pei-Jung
通讯作者：
Lu, Pei-Jung